Rights issue attached to capital raising???, page-5

They cannot afford a CR and they know it!

That is why all the clinical trial effort is either winding down or stopped. That way they will have enough money to re-market Vivagel and Viraleze products and perhaps get some return for DEP (albeit at a discount, I suspect).

There is some revenue from the work the scientists do for partners. But I doubt this covers their costs and they don't seem to have much else to do. Others here might know how many recently ex Starpharma people are out there having changed jobs or just looking.